Big Pharma Casts Immune Checkpoint Net Wide Across Tumor Types
Executive Summary
Encouraged by data for a number of immune checkpoint molecules, Bristol, Merck and Roche are moving forward fast with development in many cancers, including melanoma, kidney cancer, lung cancer and hematologic malignancies. Trials in diseases with high unmet need could allow a faster route to approval for drugs in the anti-PD1 family.